Ronald Perelman’s net worth, biography, fact, career, awards and life story

What is Ronald Perelman’s net worth?Ronald Perelman is an American businessman and investor who has a net worth of $4 billion dollars. Ronald Perelman is best known for his company MacAndrews & Forbes Holdings Inc., which he used in the 1980s to acquired cosmetics company Revlon. He has investments in a wide range of industries including those dealing with groceries, cigars, licorice, makeup, cars, television, camping supplies, banks, comic book publishing, and more. At various times in the 1980s he was referred to as the richest person in America. He was also considered one of the most-feared corporate raiders of the time. In recent decades his net worth has been as high as $20 billion. Ron’s fortune took a major hit amid the COVID-19 crisis, dropping from $14 billion to $4 billion in under a year in 2020.? Compare Ronald Perelman’s Net WorthEarly LifeRonald Owen Perelman was born in Greensboro, North Carolina on January 1, 1943. He was raised in Elkins Park, Pennsylvania, near Philadelphia. Perelman’s father Raymond was a successful buyout artist who went on to teach his son the ins and outs of running a company. By 11, Ronald regularly attended meetings with his father and is said to have received very harsh criticism for even the slightest of business mistakes.In 1964 Ronald graduated from the Wharton School at the University of Pennsylvania. He received his master’s in 1966.During his Freshman year at Wharton, Perelman and his father paid $800,000 for a Brewery. Three years later they sold the business for $1.8 million, netting a $1 million profit. Ron and his father continued buying distressed assets, improving the core business and then selling the company for a healthy profit. Ron just assumed he would soon take over the family investment business from his father Raymond. In the late 1970s, Raymond made it clear he was not stepping down any time soon. In 1978 Ronald resigned in anger and the two barely spoke for the next six years.SuccessIn 1965 Ronald married Faith Golding. They met while taking a cruise to Israel. A real estate and banking heiress, at the time they married Faith was already worth $100 million personally. That’s the same as around $800 million today. Faith and Ron ended up adopting three children, Steven, Josh, and Hope, before their biological child, Debra, was born. They divorced in 1984.In 1978, soon after resigning from his father’s company, Ron borrowed funds from his wife to acquire Cohen-Hatfield Jewelers. He soon moved to sell off the company’s retail locations and reduced the company to concentrate exclusively on wholesale. These moves earned him $15 million within a year of acquiring the business.In 1980 he paid $45 million for would become his longtime holding company, MacAndrew & Forbes, a licorice and chocolate distributor. He sold off the chocolate assets. In 1984 he took the company private in a $95 million deal. Through MacAndrew & Forbes Ron would go on to acquire and sell dozens of businesses in a wide range of industries. Notable early acquisitions included Technicolor Inc., Compact Video, Consolidated Cigar Holdings Ltd, Pantry Pride supermarkets, and New World Entertainment.RevlonPerelman financed many of his transactions using Michael Milken’s infamous junk bonds. His most famous deal was the 1985 acquisition of cosmetics company Revlon to Pantry Pride.Before he showed any interest, Revlon’s public market cap value was $365 million. Ron ended up paying $1.75 billion for the company using around $3 billion in borrowed debt to finance the deal. Why $3 billion? After paying roughly $1.8 billion to Revlon shareholders, he also incurred $900 million in financing costs and fees.For the next several decades the company struggled under its multi-billion-dollar debt load. Not long after the deal, Revlon lightened its load by selling some assets. For example Ron sold Revlon’s vision care division for around $575 million. Today he owns 87% of Revlon.In the late 1980s Ron acquired five bankrupt Savings & Loans. In 1993 the banks were sold to Bank of America for $1 billion.Personal LifeRon’s second marriage was to Claudia Cohen, with whom he had a daughter named Samantha, in 1990. The couple divorced in 1993. Perelman married Patricia Duff in 1995. They had a daughter, named Caleigh, in 1996. That same year, the couple divorced. He married his fourth wife, actress Ellen Barkin, in 2000. That marriage lasted until 2005. In 2010 he married his fifth and current wife, Anna Chapman, with whom he has two children.Art CollectionRonald for many years owned an extremely impressive and valuable collection of art. At its peak the collection was valued at $6 billion. He has sold off many pieces from the collection in recent years. His collection at times has included works by Jasper Johns, Francis Bacon, Mark Rothko, Ed Ruscha, Gerhard Richter, Cy Twombly and many more.Real Estate and ToysPerelman’s primary residence is a 40-room mansion on Georgica Pond on 60-acers in East Hampton that dates back to 1899. The property’s value is extremely difficult to peg due to its size and rarity for the area. It might be worth north of $200 million. He at one point owned a Gulfstream G650.
Read More

Stéphane Bancel’s net worth, biography, fact, career, awards and life story

What is Stéphane Bancel’s Net Worth and Salary?Stéphane Bancel is a French billionaire businessman who has a net worth of $6 billion. Stéphane Bancel best known as the CEO of the biotechnology and pharmaceutical company Moderna. Focusing on mRNA vaccines, the company released its first commercial product, the COVID-19 vaccine, in 2020. Prior to joining Moderna, Bancel was the CEO of the multinational biotechnology company bioMérieux.Stock HoldingsModerna went public in 2018 with the largest biotech IPO of all time, raising $604 million.Today Bancel directly owns a little over 5% of Moderna. He also has the ability to own another, roughly 5%, through stock options based on performance goals.Early Life and EducationStéphane Bancel was born on July 20, 1972 in Marseille, France to a doctor mother and an engineer father. Growing up, he was skilled in math and science. For his higher education, Bancel studied engineering at CentraleSupélec, earning his master’s degree; he subsequently obtained another master’s in biological engineering from the University of Minnesota. Bancel went on to receive an MBA degree from Harvard Business School.Career BeginningsBancel started his career as a sales director at the pharmaceutical company Eli Lilly and Company, before becoming head of operations for its Belgium location. Following this, he became the CEO of the French multinational biotechnology company bioMérieux, which provides diagnostic solutions via instruments and services to determine sources of contamination and disease. Among other things, the company’s products are used for monitoring and cancer screening, diagnosing infectious diseases, and inspecting foods, cosmetics, and pharmaceuticals for microorganisms. As CEO, Bancel was credited with improving the margins of bioMérieux.Moderna BackgroundIn 2011, Bancel became the CEO of the Cambridge, Massachusetts-based biotechnology and pharmaceutical company Moderna, which had been founded the previous year. The company raised $40 million by the end of 2012, and reached unicorn valuation. In early 2013, Moderna signed a five-year option agreement with biotechnology and pharmaceutical company AstraZeneca to develop mRNA treatments in a number of therapeutic medical areas. Later in the year, Moderna received $25 million from DARPA to develop messenger RNA therapeutics. The company continued to test mRNA technology over the subsequent years, and in 2018 opened a 200,000-square-foot facility in Norwood, Massachusetts for the purposes of clinical and preclinical work as well as manufacturing. At the end of 2018, Moderna made the largest initial public offering in the history of biotech, ultimately raising $621 million. In addition to serving as the CEO, Bancel owns around 9% stake in Moderna.COVID-19 VaccineAlong with the Biomedical Advanced Research and Development Authority and the US National Institute of Allergy and Infectious Diseases, Moderna developed a COVID-19 vaccine using mRNA technology. In March of 2020, the FDA approved clinical trials of the vaccine; after trials wrapped in November, it was confirmed that the vaccine was 100% effective in preventing severe COVID-19 cases. The vaccine was subsequently issued an emergency use authorization in the United States, and soon after in Canada and the European Union as well.The COVID-19 vaccine, sold under the brand Spikevax, was approved in 70 countries in 2021. Moderna had an international team of 3,000, with 21 commercial subsidiaries operating around the world. Also in 2021, Moderna started working on a combined influenza vaccine and COVID-19 vaccine booster.Other Business EndeavorsIn his other business ventures, Bancel is a partner at Flagship Pioneering, a life-sciences venture capital firm based in Cambridge, Massachusetts that both invests in and incubates companies. Moderna is among its portfolio companies, as is Novomer and Indigo Agriculture. Meanwhile, Bancel has served on the boards of Indigo Agriculture, the Museum of Science in Boston, and the German diagnostics and research company QIAGEN.
Read More